Natixis Lowers Stake in Boston Scientific Co. (NYSE:BSX)

Natixis trimmed its stake in shares of Boston Scientific Co. (NYSE:BSX - Free Report) by 16.8% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 529,014 shares of the medical equipment provider's stock after selling 106,994 shares during the quarter. Natixis' holdings in Boston Scientific were worth $47,252,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in BSX. NWK Group Inc. boosted its holdings in Boston Scientific by 2.1% in the 4th quarter. NWK Group Inc. now owns 75,724 shares of the medical equipment provider's stock valued at $6,764,000 after purchasing an additional 1,571 shares during the period. Norinchukin Bank The raised its position in shares of Boston Scientific by 9.1% in the fourth quarter. Norinchukin Bank The now owns 65,971 shares of the medical equipment provider's stock worth $5,893,000 after buying an additional 5,484 shares in the last quarter. Ossiam boosted its stake in Boston Scientific by 2.4% during the fourth quarter. Ossiam now owns 796,786 shares of the medical equipment provider's stock valued at $71,169,000 after buying an additional 18,378 shares during the period. BI Asset Management Fondsmaeglerselskab A S grew its position in Boston Scientific by 109.9% during the fourth quarter. BI Asset Management Fondsmaeglerselskab A S now owns 270,107 shares of the medical equipment provider's stock worth $24,126,000 after buying an additional 141,398 shares in the last quarter. Finally, Capital International Inc. CA increased its stake in Boston Scientific by 193.1% in the 4th quarter. Capital International Inc. CA now owns 148,059 shares of the medical equipment provider's stock worth $13,225,000 after acquiring an additional 97,550 shares during the last quarter. Hedge funds and other institutional investors own 89.07% of the company's stock.

Boston Scientific Trading Up 4.2 %

NYSE:BSX traded up $3.96 during mid-day trading on Wednesday, reaching $99.01. 12,865,196 shares of the company's stock traded hands, compared to its average volume of 6,413,801. The company has a 50 day moving average price of $99.00 and a 200-day moving average price of $94.55. The firm has a market capitalization of $146.44 billion, a price-to-earnings ratio of 79.21, a PEG ratio of 2.79 and a beta of 0.73. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.08 and a quick ratio of 1.02. Boston Scientific Co. has a 12-month low of $67.80 and a 12-month high of $107.17.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its earnings results on Wednesday, April 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.67 by $0.08. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. The firm had revenue of $4.66 billion for the quarter, compared to analysts' expectations of $4.57 billion. On average, sell-side analysts predict that Boston Scientific Co. will post 2.85 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the stock. Raymond James upped their price objective on shares of Boston Scientific from $119.00 to $122.00 and gave the stock a "strong-buy" rating in a research report on Thursday, February 6th. Truist Financial decreased their price target on shares of Boston Scientific from $120.00 to $113.00 and set a "buy" rating on the stock in a report on Friday, April 11th. Stifel Nicolaus upped their target price on shares of Boston Scientific from $100.00 to $115.00 and gave the stock a "buy" rating in a research report on Thursday, February 6th. Citigroup increased their target price on Boston Scientific from $107.00 to $122.00 and gave the company a "buy" rating in a research note on Thursday, February 6th. Finally, Piper Sandler lifted their price target on Boston Scientific from $95.00 to $115.00 and gave the stock an "overweight" rating in a research note on Monday, February 3rd. One research analyst has rated the stock with a hold rating, twenty-two have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Buy" and an average target price of $110.22.

Insiders Place Their Bets

In other Boston Scientific news, SVP Vance R. Brown sold 4,826 shares of the company's stock in a transaction that occurred on Monday, April 21st. The stock was sold at an average price of $95.09, for a total transaction of $458,904.34. Following the transaction, the senior vice president now owns 36,193 shares in the company, valued at approximately $3,441,592.37. This represents a 11.77 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Daniel J. Brennan sold 15,087 shares of the firm's stock in a transaction that occurred on Wednesday, February 12th. The shares were sold at an average price of $105.07, for a total value of $1,585,191.09. Following the completion of the transaction, the chief financial officer now owns 241,451 shares of the company's stock, valued at approximately $25,369,256.57. The trade was a 5.88 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 138,009 shares of company stock worth $14,407,381. 0.50% of the stock is currently owned by corporate insiders.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.